Rosiglitazone Ameliorates Spinal Cord Injury via Inhibiting Mitophagy and Inflammation of Neural Stem Cells

Figure 1

Rosi ameliorates spinal cord injury, inhibits inflammation factors, and promotes NSC proliferation. (a) BBB scores in SCI rats with or without Rosi treatment. (b) The levels of IL-1β and IL-6 in NSCs by ELISA kit. (c) Representative plots of flow cytometry. The Nestin⁺/BrdU⁺ cells in the red rectangle are those of interest. (d) Flow cytometry results showing Nestin⁺ cells and Nestin⁺/BrdU⁺ cells in the spinal cord of SCI rats undergoing DMSO or Rosi treatments. (e, f) CCK-8 measurement and cells counting in NSCs treated with DMSO or different concentrations of Rosi. ^# versus 30 μg/mL Rosi. (g, h) Images of Edu staining in NSCs treated by DMSO or Rosi. DAPI (blue) and Edu (green) represent the nucleus and the newly synthesized DNA, respectively. (i) Effects of Rosi on ATP production. ^# versus 30 μg/mL Rosi. (j) Effects of Rosi on ATP levels produced by glycolysis. ^# versus 30 μg/mL Rosi. (k) Effects of different Rosi concentrations on intracellular glucose content. ^# versus 20 μg/mL Rosi. Data represent six (a) or three (b, c, e–g, i–k) independent experiments and are expressed as (a–c, e–g, i–k). versus DMSO treatment.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)